SecBot SecBot
SECBOTREPLAY Home › Report › CTKB

CTKB · Boston Partners stake 6.16%

Cytek Biosciences, Inc. · SC 13G/A filed Nov 13, 2026 at 11:47 ET

At the news

NEUTRALIMPACT 2/10

SC 13G/A filed Nov 13, 2026 at 11:47 ET

Boston Partners filed an amended Schedule 13G disclosing a 6.16% passive stake in Cytek Biosciences as of September 30, 2026, up from a prior 5.6% stake. The increase is modest and routine for a passive institutional investor.

  • Boston Partners reported beneficial ownership of 8,002,638 shares of Cytek Biosciences common stock as of September 30, 2026.
  • The stake represents 6.16% of shares outstanding, up from 5.6% in the prior filing.
  • Boston Partners is a registered investment adviser filing under Rule 13d-1(b) as a passive investor.
  • The filing certifies the securities were acquired and are held in the ordinary course of business, not to influence control.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access